Peanut allergy treatment is effective but not always easy to tolerate, new review shows

Aimmune Therapeutics (AIMT) picked up an independent endorsement Sunday for its oral challenge approach to protecting people against severe peanut allergy. However, the newly published review also highlights some tolerability concerns that have previously stoked investor concerns.

The endorsement, published in the New England Journal of Medicine, accompanied new Phase 3 data on Aimmune’s product, called AR101.